$24.49
4.82% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US45258J1025
Symbol
IMVT

Immunovant Inc Stock price

$24.49
-4.24 14.76% 1M
-1.51 5.81% 6M
-17.64 41.87% YTD
-19.07 43.78% 1Y
+16.65 212.37% 3Y
+8.25 50.80% 5Y
+14.54 146.13% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-1.24 4.82%
ISIN
US45258J1025
Symbol
IMVT
Sector

Key metrics

Market capitalization $3.59b
Enterprise Value $3.12b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 7.99
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-352.46m
Free Cash Flow (TTM) Free Cash Flow $-272.30m
Cash position $472.94m
EPS (TTM) EPS $-2.22
P/E forward negative
Short interest 19.66%
Show more

Is Immunovant Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Immunovant Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Immunovant Inc forecast:

13x Buy
100%

Analyst Opinions

13 Analysts have issued a Immunovant Inc forecast:

Buy
100%

Financial data from Immunovant Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.29 0.29
79% 79%
-
-0.29 -0.29
79% 79%
-
- Selling and Administrative Expenses 65 65
28% 28%
-
- Research and Development Expense 287 287
40% 40%
-
-352 -352
37% 37%
-
- Depreciation and Amortization 0.29 0.29
79% 79%
-
EBIT (Operating Income) EBIT -352 -352
36% 36%
-
Net Profit -323 -323
27% 27%
-

In millions USD.

Don't miss a Thing! We will send you all news about Immunovant Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunovant Inc Stock News

Neutral
Seeking Alpha
one day ago
Immunovant aims to initiate a pivotal registration study for IMVT-1402 targeting Graves' Disease by the end of 2024, with 4–5 trials in other IgG-mediated autoimmune disorders by March 2025. IMVT-1402 offers deeper IgG suppression without increasing LDL cholesterol like Batoclimab does. Financial caution is advised as Immunovant's cash runway only extends for 12 months, likely necessitating IMV...
Neutral
GlobeNewsWire
18 days ago
Presents Current Treatment Practices, Emerging Drugs, Market Share of Individual Therapies, and FcRn Inhibitor Market Size from 2020 to 2034 Presents Current Treatment Practices, Emerging Drugs, Market Share of Individual Therapies, and FcRn Inhibitor Market Size from 2020 to 2034
Neutral
GlobeNewsWire
about 2 months ago
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported development updates and financial results for its fiscal second quarter ended September 30, 2024.
More Immunovant Inc News

Company Profile

Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.

Head office United States
CEO Peter Salzmann
Employees 207
Founded 2018
Website www.immunovant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today